Technical Analysis for FRTX - Fresh Tracks Therapeutics

Grade Last Price % Change Price Change
F 0.72 -2.72% -0.02
FRTX closed down 16.48 percent on Friday, October 4, 2024, on 5 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish -2.72%
Narrow Range Bar Range Contraction -2.72%
Below Lower BB Weakness -2.72%
Gapped Down Weakness -2.72%
Oversold Stochastic Weakness -2.72%
Stochastic Buy Signal Bullish -18.75%
Narrow Range Bar Range Contraction -18.75%
Earnings Movers Other -18.75%
Oversold Stochastic Weakness -18.75%
Narrow Range Bar Range Contraction -18.75%

   Recent Intraday Alerts

Alert Time
Gapped Down (Full) about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 2 % about 3 hours ago
Down 1% about 3 hours ago
Gapped Down (Full) 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fresh Tracks Therapeutics Description

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Disease Inflammatory

Is FRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.1
52 Week Low 0.5603
Average Volume 16,346
200-Day Moving Average 0.91
50-Day Moving Average 0.91
20-Day Moving Average 0.91
10-Day Moving Average 0.88
Average True Range 0.03
RSI (14) 20.00
ADX 25.14
+DI 24.09
-DI 58.20
Chandelier Exit (Long, 3 ATRs) 0.87
Chandelier Exit (Short, 3 ATRs) 0.82
Upper Bollinger Bands 0.99
Lower Bollinger Band 0.82
Percent B (%b) -0.45
BandWidth 19.80
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0145
Fundamentals Value
Market Cap 4.39 Million
Num Shares 5.97 Million
EPS -2.32
Price-to-Earnings (P/E) Ratio -0.32
Price-to-Sales 0.59
Price-to-Book 0.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.74
Resistance 3 (R3) 0.74 0.74 0.74
Resistance 2 (R2) 0.74 0.74 0.74 0.74
Resistance 1 (R1) 0.74 0.74 0.74 0.74 0.74
Pivot Point 0.74 0.74 0.74 0.74 0.74
Support 1 (S1) 0.74 0.74 0.74 0.74 0.74
Support 2 (S2) 0.74 0.74 0.74 0.74
Support 3 (S3) 0.74 0.74 0.74
Support 4 (S4) 0.74